Show simple item record

dc.contributor.authorBenafif, Sen_US
dc.contributor.authorKote-Jarai, Zen_US
dc.contributor.authorEeles, RAen_US
dc.contributor.authorPRACTICAL Consortiumen_US
dc.coverage.spatialUnited Statesen_US
dc.date.accessioned2018-11-26T14:30:55Z
dc.date.issued2018-08en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/29348298en_US
dc.identifier1055-9965.EPI-16-1046en_US
dc.identifier.citationCancer Epidemiol Biomarkers Prev, 2018, 27 (8), pp. 845 - 857en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2951
dc.identifier.eissn1538-7755en_US
dc.identifier.doi10.1158/1055-9965.EPI-16-1046en_US
dc.description.abstractProstate cancer is the most common cancer in men in Europe and the United States. The genetic heritability of prostate cancer is contributed to by both rarely occurring genetic variants with higher penetrance and moderate to commonly occurring variants conferring lower risks. The number of identified variants belonging to the latter category has increased dramatically in the last 10 years with the development of the genome-wide association study (GWAS) and the collaboration of international consortia that have led to the sharing of large-scale genotyping data. Over 40 prostate cancer GWAS have been reported, with approximately 170 common variants now identified. Clinical utility of these variants could include strategies for population-based risk stratification to target prostate cancer screening to men with an increased genetic risk of disease development, while for those who develop prostate cancer, identifying genetic variants could allow treatment to be tailored based on a genetic profile in the early disease setting. Functional studies of identified variants are needed to fully understand underlying mechanisms of disease and identify novel targets for treatment. This review will outline the GWAS carried out in prostate cancer and the common variants identified so far, and how these may be utilized clinically in the screening for and management of prostate cancer. Cancer Epidemiol Biomarkers Prev; 27(8); 845-57. ©2018 AACR.en_US
dc.format.extent845 - 857en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
dc.titleA Review of Prostate Cancer Genome-Wide Association Studies (GWAS).en_US
dc.typeJournal Article
dcterms.dateAccepted2017-10-27en_US
rioxxterms.versionofrecord10.1158/1055-9965.EPI-16-1046en_US
rioxxterms.licenseref.startdate2018-08en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfCancer Epidemiol Biomarkers Preven_US
pubs.issue8en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics
pubs.publication-statusPublisheden_US
pubs.volume27en_US
pubs.embargo.termsNot knownen_US
icr.researchteamOncogeneticsen_US
dc.contributor.icrauthorEeles, Rosalinden_US
dc.contributor.icrauthorKote-Jarai, Zsofiaen_US
dc.contributor.icrauthorBenafif, Sarahen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record